Search

UK asthma prevalence fell significantly between 1993 and 2000. In children aged <5 years hospital admissions for asthma fell by 52% and primary care presentations in children under 14 years by over 40%. From 1994 to 2000, primary care consultations for acute respiratory infections in all age groups fell by 36%, and for the common cold by 46%. Isolates for respiratory syncytial virus notified to the Health Protection Agency voluntary reporting scheme fell by 56% between 1993 and 2003. Falls in UK birth rate and improvements in living conditions were reported by the Office of National Statistics over this time. The authors hypothesise that the fall in asthma reflects a fall in respiratory infections, the most important proximal trigger for asthma exacerbations, and that this in turn may be related to a fall in household members to a number too low for effective virus transmission. Future research into the prevalence of asthma must consider the effect of changing respiratory virus burden on populations. [ABSTRACT FROM AUTHOR]

Aims: Chronic heart failure reduces quality and quantity of life and is expensive for healthcare systems. Medical treatment relies on guideline-directed therapy, but clinical follow-up and remote management is highly variable and poorly effective. New remote management strategies are needed to maintain clinical stability and avoid hospitalizations for acute decompensation., Methods and Results: The CardioMEMS Post-Market Study is a prospective, international, single-arm, multicentre, open-label study (NCT02954341) designed to examine the feasibility of haemodynamic guided heart failure management using a small pressure sensor permanently implanted in the pulmonary artery (PA). Daily uploaded PA pressures will be reviewed weekly to remotely guide medical management of patients with persistent NYHA Class III symptoms at baseline and a hospitalization in the prior 12 months. The study will enrol up to 800 patients from 85 sites across the United Kingdom, Europe, and Australia. The primary safety endpoint will assess device or system-related complications or sensor failures after 2 years of follow-up. Efficacy will be estimated after 1 year of follow-up comparing HF hospitalization rates before and after sensor implantation. Observational endpoints will include mortality, patient, and investigator monitoring compliance, PA pressure changes, quality of life, and several pre-defined subgroup analyses., Conclusions: The CardioMEMS Post-Market Study will investigate the generalizability of remote haemodynamic guided HF management in a number of national settings. The results may support the more widespread implementation of this novel clinical management approach., (© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.)